|
(MoneyNewsWire.Net, May 04, 2018 ) The Indian peptides market is expected to reach USD 883.0 Million by 2022 from USD 381.8 Million in 2016, at a CAGR of 15.0%. Increasing prevalence of chronic diseases such as diabetes, cancer, and osteoporosis and favorable government policies for the pharmaceutical sector are expected to drive the growth of this market.
Explore More Information about report @ https://www.researchcosmos.com/reports/india-peptides-and-heparin-market-analysis-and-forecast-to-2022-growth-opportunity-assessment/6993630
The Indian peptides market is segmented by type and application. By type, the Indian peptides market is segmented into calcitonin-salmon, glucagon, insulin, leuprolide acetate, octreotide acetate, teriparatide, exenatide, bivalirudin, glatiramer acetate, eptifibatide, triptorelin, liraglutide, and other molecules. Insulin segment dominated the Indian peptides market in 2016. The growing incidence of diabetes in India are the key factors driving the growth of this segment.
On the basis of application, the Indian peptides market segmented into diabetes, cancer, cardiovascular disease (CVD), gynecological application, infectious diseases, osteoporosis, and other applications (acromegaly, multiple sclerosis, and hepatitis). Diabetes segment accounts for the largest segment and is also the fastest growing application segment in the market. The increasing prevalence and incidence of diabetes and rising awareness about the benefits of early diagnosis are the major factors driving the growth of this market.
Biocon Limited, Sun Pharmaceutical Industries Limited, Wokhardt Limited, Intas Pharmaceutical Limited, Cipla Limited, Emcure Pharmaceutical Limited, and Zydus Cadila have been identified as the top players in this market. These companies have a broad product portfolio with comprehensive features. These companies have products for all end users in this segment, a strong geographical presence, and more importantly, focus on continuous product innovations.
Request free sample @ https://www.researchcosmos.com/request/6993630
The Indian heparin market is expected to reach USD 170.2 million by 2022 from USD 127.8 million in 2016, at a CAGR of 4.9%. The growing incidence of coagulation disorders and government support for pharmaceutical companies are expected to drive the growth of this market.
The Indian heparin market is segmented by type. By type, the Indian heparin market is segmented into heparin sodium, enoxaparin sodium, fondaparinux, and dalteparin sodium. The enoxaparin sodium segment dominated the Indian peptides market in 2016. The growing incidence of coagulation disorder in India are the key factors driving the growth of this segment.
Availability of alternative drugs and the high degree of market consolidation are restraining the growth of the Indian peptides and heparin market. For example, the top players in this market are large & well established and enjoy a high degree of brand loyalty.
Emcure Pharmaceutical Pvt. Ltd., Cipla Ltd., Gland Pharma Limited, Troikaa Pharmaceuticals Ltd., and Biological E Limited have been identified as the top players in this market. These companies have a broad product portfolio with comprehensive features. These companies have products for all end users in this segment, a strong geographical presence, and more importantly, focus on continuous product innovations.
Check for discount @ https://www.researchcosmos.com/discount/6993630
About Us:
Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.
Research Cosmos
Dani Rodriguez
+1 888 709 8757
dani@researchcosmos.com
Source: EmailWire.Com 
|
